Evaluation of the Arabin cervical pessary for prevention of preterm birth in women with a twin pregnancy and short cervix (STOPPIT-2) : An open-label randomised trial and updated meta-analysis by Norman, Jane E. et al.
RESEARCH ARTICLE
Evaluation of the Arabin cervical pessary for
prevention of preterm birth in women with a
twin pregnancy and short cervix (STOPPIT-2):
An open-label randomised trial and updated
meta-analysis
Jane E. NormanID
1*, John NorrieID2, Graeme MacLennan3, David CooperID3,
Sonia WhyteID
4, Sue ChowdhryID




8, Stephen C. RobsonID
9, Steven Thornton10, Mark
D. Kilby11, Neil MarlowID
12, Sarah J. StockID
5, Phillip R. Bennett13, Jane Denton14, on
behalf of the STOPPIT-2 collaborative group14¶
1 Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom, 2 Edinburgh Clinical Trials Unit,
University of Edinburgh, Edinburgh, United Kingdom, 3 Centre for Healthcare Randomised Trials, University
of Aberdeen, Aberdeen, United Kingdom, 4 Tommy’s Centre for Maternal and Fetal Health,AU : Ichanged}MRCCentreforMaternalandFetalHealth}to}MRCCentreforReproductiveHealth}perevidenceonline; includingathttps : ==www:ed:ac:uk=centre   reproductive   health:Correct?MRC Ce tr for
Reproductive Health, University of Edinburgh, Edinburgh, United Kingdom, 5 Usher Institute, University of
Edinburgh, Edinburgh, United Kingdom, 6 Nuffield Department of Population Health, University of Oxford,
Oxford, United Kingdom, 7 NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom,
8 Department of Women’s and Children’s Health, King’s College London, London, United Kingdom,
9 Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, 10 Barts and The
London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom,
11 Fetal Medicine Centre, Birmingham Women’s and Children’s NHS Foundation Trust and College of
Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 12 Elizabeth Garrett
Anderson Institute for Women’s Health, University College London, London, United Kingdom, 13 Institute for
Reproductive and Developmental Biology, Imperial College London, London, United Kingdom, 14 Multiple
Births Foundation, London, United Kingdom




Preterm-labour-associated preterm birth is a common cause of perinatal mortality and mor-
bidity in twin pregnancy. We aimed to test the hypothesis that the Arabin pessary would
reduce preterm-labour-associated preterm birth by 40% or greater in women with a twin
pregnancy and a short cervix.
Methods and findings
We conducted an open-label randomised controlled trial in 57 hospital antenatal clinics in
the UK and Europe. From 1 April 2015 to 14 February 2019, 2,228 women with a twin preg-
nancy underwent cervical length screening between 18 weeks 0 days and 20 weeks 6 days
of gestation. In total, 503 women with cervical length� 35 mm were randomly assigned to
pessary in addition to standard care (n = 250, mean age 32.4 years, mean cervical length 29
mm, with pessary inserted in 230 women [92.0%]) or standard care alone (n = 253, mean
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age 32.7 years, mean cervical length 30 mm). The pessary was inserted before 21 com-
pleted weeks of gestation and removed at between 35 and 36 weeks or before birth if earlier.
The primary obstetric outcome, spontaneous onset of labour and birth before 34 weeks 0
days of gestation, was present in 46/250 (18.4%) in the pessary group compared to 52/253
(20.6%) following standard care alone (adjusted odds ratio [aOR] 0.87 [95% CI 0.55–1.38],
p = 0.54). The primary neonatal outcome—a composite of any of stillbirth, neonatal death,
periventricular leukomalacia, early respiratory morbidity, intraventricular haemorrhage,
necrotising enterocolitis, or proven sepsis, from birth to 28 days after the expected date of
delivery—was present in 67/500 infants (13.4%) in the pessary group compared to 76/506
(15.0%) following standard care alone (aOR 0.86 [95% CI 0.54–1.36], p = 0.50). The posi-
tive and negative likelihood ratios of a short cervix (�35 mm) to predict preterm birth before
34 weeks were 2.14 and 0.83, respectively. A meta-analysis of data from existing publica-
tions (4 studies, 313 women) and from STOPPIT-2 indicated that a cervical pessary does
not reduce preterm birth before 34 weeks in women with a short cervix (risk ratio 0.74 [95%
CI 0.50–1.11], p = 0.15). No women died in either arm of the study; 4.4% of babies in the
Arabin pessary group and 5.5% of babies in the standard treatment group died in utero or in
the neonatal period (p = 0.53). Study limitations include lack of power to exclude a smaller
than 40% reduction in preterm labour associated preterm birth, and to be conclusive about
subgroup analyses.
Conclusions
These results led us to reject our hypothesis that the Arabin pessary would reduce the risk
of the primary outcome by 40%. Smaller treatment effects cannot be ruled out.
Trial registration
ISRCTN Registry ISRCTN 02235181.
ClinicalTrials.gov NCT02235181.
Author summary
Why was this study done?
• Preterm-labour-associated preterm birth is common in twin pregnancy, and is an
important cause of perinatal mortality and morbidity.
• There is controversy on the clinical effectiveness and cost-effectiveness of the Arabin
pessary for the prevention of preterm birth in women with a twin pregnancy and a short
cervix.
What did the researchers do and find?
• We randomised 503 women with a cervical length of 35 mm or less to either standard
care (according to National Institute for Health and Care Excellence [NICE] guidelines)
or standard care and an Arabin pessary, inserted before 21 weeks gestation.
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• The primary obstetric outcome was spontaneous onset of labour and birth before 34
weeks 0 days of gestation; the primary neonatal outcome was a composite adverse
outcome.
• We found no differences in rates of the primary obstetric and neonatal outcomes
between the 2 groups.
What do these findings mean?
• Our findings indicate that any reduction in preterm-labour-associated preterm birth
conferred by the Arabin pessary is less than 40%.
• Our findings indicate that a cervical length scan between 18 weeks 0 days and 20 weeks
6 days in women with a twin pregnancy and using a threshold length of 35 mm was inef-
fective at ruling in or ruling out preterm-labour-associated preterm birth.
Introduction
Multiple pregnancy accounts for around 3% of births worldwide, the majority being twin preg-
nancies. Preterm birth is significantly more common in twins [1], and hence twin pregnancies
are associated with higher rates of perinatal death and morbidity and higher healthcare costs
compared to singleton pregnancies.
Three strategies have been trialled to determine if they prevent preterm birth of twins, but
none have proven effective. Progesterone appears ineffective following the most recent system-
atic review (2017) [1], although there is controversy around this. Cervical cerclage may have a
role in women with a very short cervix (cervical length of<15 mm), or in the presence of a
dilated cervix, but is ineffective overall [2]. The placement of a silicone pessary around the cer-
vix, the Arabin pessary, has also been advocated. Initial studies in women with a singleton
pregnancy suggested a strong treatment effect in the prevention of preterm birth in women
with singleton pregnancy and a short cervix (odds ratio [OR] 0.18 [95% CI 0.08–0.37], p<
0.001AU : }p < 0:0001}changedto}p < 0:001}perPLOSMedstyle:) [3]. However, a re ent meta-analysis suggests that a c rvical pessary has no impact on
preterm birth prevention in these women (relative risk 0.80 [95% CI 0.43–1.49], p = 0.48) [4].
In women with twin pregnancy, there have been 3 studies. Results for 1 of 2 studies [5,6]
including women with a short cervix, and a subgroup of women with a short cervix in another
study [7], suggested that pessary placement reduces preterm birth. In contrast, in 2 studies of
unselected women with twin pregnancy, there was no overall effect [7,8]. If effective, the Ara-
bin pessary would potentially have wide applicability for the prevention of prematurity in twin
pregnancies in women with a short cervix. The device itself is relatively inexpensive (current
UK retail price £48) and can be inserted as an outpatient procedure, and side effects are
reported to be ‘acceptable’ [7]. However, to date, trial results are conflicting, and sample sizes
modest, and include results from a post hoc determination of cervical length threshold [7].
STOPPIT-2 is an open randomised controlled trial of the Arabin pessary to prevent
preterm birth in twin pregnancy in woman with a short cervix (ISRCTN02235181,
NCT02235181). The acronym is a reference to the STOPPIT study [9], which tested the effec-
tiveness of progesterone for the prevention of preterm birth in twins. STOPPIT-2 was designed
to test the hypothesis that, compared to standard treatment alone, the Arabin cervical pessary
and standard care reduces the frequency of spontaneous labour associated with preterm birth
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in women with a twin pregnancy and cervical length� 35 mm (‘short’ cervix), thus reducing
adverse neonatal outcomes and healthcare costs. We also explored acceptability to pregnant
women and a priori the effectiveness in 2 subgroups: women with a cervical length� 25 mm,
and women with a monochorionic twin pregnancy.
Methods
Study design and participants
STOPPIT-2 was an open-label randomised controlled superiority trial conducted in 57 antena-
tal clinics caring for women with multiple pregnancy at 56 UK NHS hospitals and 1 hospital in
Belgium. The study protocol is published [10].
Participants were women with an uncomplicated twin pregnancy attending for antenatal
care during the recruitment period of the study. The study was in 2 phases—(i) screening for
eligibility by ultrasound and (ii) randomisation to treatment. All of the following inclusion cri-
teria were required for eligibility for both the screening and treatment phases of the study:
twin pregnancy (monochorionic or dichorionic), known chorionicity (as defined by first tri-
mester ultrasound screening), current gestation�20 weeks + 6 days (as established by scan at
�16 weeks according to NICE guidelines), age 16 years or older, and willingness to participate
in both the screening and treatment phase of the study. Women with a short cervix (intended
to be at or below the 30th centile) identified during the screening phase were eligible for inclu-
sion in the treatment phase. For the first 6 months of the trial, the cervical length threshold for
inclusion used was�30 mm, but this was changed to�35 mm after 6 months when it became
clear that the 30th centile of our target population was 35 mm [10]. Women with bulging fetal
membranes at the time of pessary insertion or with suspected or proven rupture of the fetal
membranes at the time of pessary insertion were excluded. All cervical length measurements
were performed using transvaginal ultrasound by a sonographer (radiographer, midwife, or
obstetrician) who had undergone training through the CLEAR programme (https://clear.
perinatalquality.org/) or the Fetal Medicine Foundation training programme (https://
fetalmedicine.org/). All participants provided written informed consent for both phases of the
study on initial recruitment. Women who were eligible to enter the treatment phase of the
study were offered the opportunity to withdraw before randomisation.
Randomisation and masking
Following written informed consent, participants who fulfilled the criteria for the treatment
phase of the study were allocated to 1 of 2 groups in a 1:1 ratio: Arabin pessary plus standard
care or standard care alone. Randomisation was carried out by entering patient details into a
web portal at the Centre for Healthcare Randomised Trials (CHaRT) at University of Aber-
deen; treatment allocation was then assigned by computer. The allocation sequence employed
minimisation with a random element (20%) using the variables study centre and chorionicity
(mono- or dichorionic).
Women were enrolled by a member of the investigator team responsible for recruitment, pes-
sary insertion, and outcome data collection at each site. It was not considered possible to mask
any of the participants, caregivers, or those collecting outcome data to treatment allocation.
Procedures
Screening phase. Participating women had a transvaginal ultrasound measurement of
cervical length performed between 18 weeks 0 days and 20 weeks 6 days of gestation by an
accredited sonographer.
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Treatment phase. Women who had a cervical length of�35 mm were consented and
allocated to standard care with or without Arabin pessary. Pessaries were inserted by an obste-
trician as an outpatient procedure after the cervical length scan and before 21 weeks of gesta-
tion. Inserting obstetricians watched a training video on pessary insertion, were provided with
written guidance on pessary management, and (at their discretion) practised pessary insertion
on a model prior to first insertion. The written guidance on pessary management included the
manufacturer’s guidance on choice of size and referred to a publication on this issue [11]. The
pessary was left in situ until 35–36 weeks 6 days of gestation unless labour started or mem-
branes ruptured, the woman asked for the pessary to be removed, or the supervising clinician
recommended removal.
Women in both groups received standard care based on NICE guidelines for management
of women with multiple pregnancy dependent upon chorionicity [12]. Women were reviewed
at 4-weekly intervals, and any adverse effects recorded. Key primary and secondary outcomes
were collected at the birth of the baby and in the neonatal period. Outcomes were abstracted
from hospital notes and entered into a web-based database by trained staff, usually a midwife.
There was no central adjudication of outcomes.
Outcomes
The primary obstetric outcome was defined as birth before 34 completed weeks following the
spontaneous onset of labour. Preterm pre-labour rupture of membranes <34 weeks with or
without contractions was included in this definition of spontaneous onset of labour assuming
birth occurred before 34 weeks; women with induction of labour or cesarean section before 34
weeks due to maternal or fetal conditions were not included in this definition of the primary
outcome.
The primary neonatal outcome was a composite of adverse outcomes, including stillbirth or
neonatal death, periventricular leukomalacia, early respiratory morbidity (defined as any need
for supplemental oxygen > 30%, continuous positive airway pressure [CPAP], intratracheal
ventilation, or surfactant replacement therapy within the first week after birth), intraventricu-
lar haemorrhage, necrotising enterocolitis, and proven sepsis, all measured up to 28 days after
the expected date of delivery [10]. Miscarriages occurring at any time from recruitment were
counted as stillbirths.
Key obstetric secondary outcomes were mean gestational age at delivery, any birth before
37 weeks of gestation, adverse events including infection and cervical trauma, acceptability of
the pessary (determined by participant questionnaire), experience of the device throughout
the study, and time of pessary removal. The frequencyAU : Pleasecheckthattheeditstothesentence}Thefrequency . . . }captureyourmeaning:Ifnot; pleaseprovidecorrectwording:of each component of th primary com-
posite neonatal outcome, birthweight, any deaths of live-born babies within the first 28 days,
and discrete episodes of bloodstream or central nervous system infection (positive blood or
cerebrospinal fluid culture, categorised by timing either within the first 72 hours or between
72 hours and discharge) were recorded.
For women screened but not randomised, we collected the frequency of birth before 34
weeks.
There were no changes to trial outcomes after commencement of the trial. A completed
CONSORT checklist is provided (see S1 CONSORT Checklist).
Statistical analysis
In a prospective UK cohort study [13], 35% of spontaneous deliveries occurred at <34 weeks.
In the ProTWIN study [7], estimated relative risk was 0.6 (B.W.Mol personal communicationAU : Pleaseaddthefirstinitialandlastnameofthepersonwhoprovidedthispersonalcommunicationðintheform}ðC:Nguyen; personalcommunication . . .Þ}:Pleaseprovidealsoaletteroremailfromthisindividualsayingthatyouhavepermissiontocitehim=herthusinthearticle; andthathe=sheatteststotheinformationbeingfactualandcorrect:
based on a subgroup of participants). We calculated that a sample size of 500 women would
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have 94% power to detect a relative risk of 0.6 for the primary obstetric outcome. Even with
imperfect compliance and losses to follow-up in each group of up to 20%, power is preserved
at 85%. Based on the ProTWIN study [7], in which the neonatal adverse outcome rate was 24%
and relative risk 0.6, this sample size would provide 97% power to detect such a difference in
the composite neonatal outcome, in the absence of any adjustment for clustering; allowing for
20% loss to follow-up (as per the obstetric primary outcome) and a between-twins intraclass
correlation of 0.5, the study would still have over 80% power for this neonatal outcome. How-
ever, we anticipated a lower outcome frequency because we recruited women with longer cer-
vices compared to the relevant subgroup in the ProTWIN study. If the prevalence of the
composite neonatal outcome was 18%, we estimated study power to be 88% at 5% significance.
Taking allAU : Pleasecheckthattheeditstothesentence}Takingall . . . }captureyourmeaning:Ifnot; pleaseprovidecorrectwording:the above into account, we ch se a sample size to ive a minim m of 0.8 power for
the neonatal outcome, which then gives 0.85 power for the obstetric outcome, given the
assumptions (clustering and dropout).
The frequency of the 2 primary outcomes in the study groups was compared in an intention
to treat analysis, using logistic regression with a fixed effect for the minimisation covariate
chorionicity, and a random effect for centre, to derive ORs and 95% confidence intervals of
treatment effect. There areAU : Pleasecheckthattheeditstothesentence}Thereareasmall . . . }captureyourmeaning:Ifnot; pleaseprovidecorrectwording:a small number of missing data points (4 and 8 mothers and there-
fore 8 and 16 babies, respectively), and we have assumed ‘no event’ where there are missing
data. We intended to use multinomial logistic regression for secondary outcomes with more
than 1 category, and linear regression for continuous secondary outcomes, adjusting for chor-
ionicity and clustering within twins. However, our planned 3-level linear regression model for
the primary neonatal outcome (babies nested within mother nested within centre, adjusting
for chorionicity) failed to converge: We therefore used standard logistic regression for the
neonatal primary outcome, adjusting for chorionicity and clustering at the mother level. For
primary outcomes, predefined subgroup analyses were performed in women with monochor-
ionic pregnancies, cervical length� 25 mm and cervical length� 28 mm; for these statistical
analyses, significance was set at the 1% level, and data are presented as 95% CIs. For theAU : Pleasecheckthattheeditstothesentence}Forthesecondary . . . }captureyourmeaning:Ifnot; pleaseprovidecorrectwording:sec-
ondary outcomes and the subgroup analyses, significance was set at the 1% level, and to
account for multiple testing, 99% CIs were obtained, but data are presented as 95% CIs. All
analyses were performed in Stata 15. We also calculated likelihood ratios for delivery before 34
weeks of gestation for women with cervical length� 35 mm.
An independent data monitoring committee (IDMC) oversaw the analysis. A detailed sta-
tistical analysis was created and signed off by the IDMC prior to study completion. The trial
was registered with the ISRCTN registry under the reference number ISRCTN98835694 and
also with ClinicalTrials.gov with the reference number NCT02235181.
Meta-analysis. On 28 November 2020, an electronic search of the database PubMed was
performed for clinical trials in twin or higher multiple pregnancy using the terms cervical pes-
sary AND preterm birth AND multiple pregnancy to identify randomised trials comparing
a cervical pessary and standard care with standard care alone for the prevention of preterm
birth in women with twin or multiple pregnancy. Studies were restricted to those published in
English. There was no attempt to contact authors of unpublished studies. We extracted data
on women with a short cervix (using the definition of short cervix relevant for each individual
study) and contacted authors for additional information where outcomes for the short cervix
subgroup were not available. Meta-analysis of these studies, together with the data from STOP-
PIT-2, was performed in Stata15 using the DerSimonian and Laird random effects model with
the heterogeneity estimate obtained from the Mantel–Haenszel model. A sensitivity analysis
was performed restricting the analysis to studies that used the Arabin pessary for the preven-
tion of preterm birth.
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Ethics statement
Ethics approval was given by South East Scotland Research Ethics Committee 02 on 29 August
2014, reference 14/SS/1031, and in Belgium on 21 September 2016, reference S58820.
Results
In total, 2,228 women consented to cervical length screening between 1 April 2015 and 14
February 2019 (participants in the UK) or 13 December 2016 and 28 December 2018 (partic-
ipants in Belgium), of whom 2,170 had a transvaginal scan. Of these, 523 were eligible for
randomisation, and 503 agreed to be randomised into the treatment phase of the study, 250
to the intervention (Arabin pessary and standard care) and 253 to standard care alone (see
participant flowchart Fig 1). The duration of pessary placement for individual women is
shown in S1 Fig. The pessary size used for the majority of participants was 70 × 25 × 32 mm;
a frequency table of pessary sizes is shown in S1 Table. The last participant visit was on 2
August 2019. Primary outcome data were available for 491/503 (97.6%) women; in the inter-
vention and the control groups, respectively, 4 and 8 women were lost to follow-up or
declined data collection but are included in the denominator for both the obstetric and neo-
natal outcomes. The 2 groups were well matched over a range of baseline measures (Table 1).
The median (interquartile range) number of women randomised to the pessary group per
centre was 3 (1–6).
The primary obstetric outcome, the proportion of women with preterm delivery before 34
weeks following spontaneous onset of labour, was 46/250 (18.4%) in the Arabin pessary and
standard care group and 52/253 (20.6%) in the standard care alone group (adjusted OR
[aOR] 0.87 [95% CI 0.55–1.38], p = 0.54; Table 2). The proportion of babies with the primary
composite neonatal outcome was 67 (13.4%) in the pessary and standard care group and 76
(15.0%) following standard care alone. The unadjusted OR for the primary neonatal outcome
was 0.88 (95% CI 0.61–1.25; p = 0.46). Our planned 3-level linear regression model for the
primary neonatal outcome (babies nested within mother nested within centre, adjusting for
chorionicity) failed to converge: We therefore used standard logistic regression for the neo-
natal primary outcome, adjusting for chorionicity and clustering at the mother level, giving
an aOR of 0.86 (95% CI 0.54–1.36; p = 0.52) (Table 3). The frequency of secondary obstetric
outcomes (Table 4), secondary neonatal outcomes (Table 5), and safety outcomes (S2 Table)
did not differ significantly between the pessary and standard care and the standard care
alone groups. Post hoc tests of interaction did not identify any differential effect on obstetric
or neonatal outcome by subgroup (S2 Fig). A time to event plot (a post hoc analysis) is
shown in S3 Fig. Results of per protocol analyses of the primary obstetric outcome (Table 6)
and the primary neonatal outcome (Table 7) were similar to those of the intention to treat
analyses.
Acceptability
All women in the standard care alone arm adhered to the intervention, with no out-of-trial
pessary insertions. The maximum potential duration of pessary placement for women who did
not deliver preterm prior to pessary removal was between 91 and 133 days (dependent on ges-
tational age at insertion). Of the 250 women allocated to Arabin pessary, 16 women declined
pessary insertion post-randomisation, and in 4 women, insertion was attempted but unsuc-
cessful. The duration of pessary placement was recorded for 217 women, with a median period
of 105 days (interquartile range 81–113) (S1 Fig). Twenty-six of 230 (11.3%) women who had
the pessary inserted asked to have it removed before the scheduled date of removal, largely due
to discomfort from the pessary (median placement of 14 days [interquartile range 6–98]), and
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in a further 13 women (5.7%) the pessary fell out after a median 69 days (interquartile range
27–100).
Of women in whom a pessary was inserted, 158/234 (67.5%) found insertion painless
or slightly uncomfortable, whereas the remainder found it uncomfortable, very uncomfort-
able, or the worst pain imaginable. Clinicians described the procedure as easy or moderately
easy in 202/234 (86.3%) cases, and difficult, very difficult, or impossible in 21/234 (9.0%)
Fig 1AU : ThereisanasteriskinFig1ðafter}Bulgingfetalmembranes}Þbutnofootnotetomatch:Pleaseaddtheappropriatefootnotetothefigurelegend; ordeletetheasteriskfromthefigure:. Participant flowchart. � Bulging fetal membr nes noted de novo since qualifying cervic l lengt scan.
https://doi.org/10.1371/journal.pmed.1003506.g001
PLOS MEDICINE STOPPIT 2
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003506 March 29, 2021 8 / 18





Age (years)—mean (range) 32.4 (17, 51) 32.7 (17, 50)
Cervical length (mm)—mean (SD) 28.8 (5.8) 29.5 (5.1)
Minimum, maximum 3.0, 35.0 7.0, 35.0
Current smoker 21 (8.4%) 20 (7.9%)
Current alcohol 1 (0.4%) 3 (1.2%)
Obstetric history
Previous livebirths
0 150 (60.0%) 135 (53.4%)
1 60 (24.0%) 77 (30.4%)
2 17 (6.8%) 27 (10.7%)
3 12 (4.8%) 8 (3.2%)
4 7 (2.8%) 3 (1.2%)
5 3 (1.2%) 3 (1.2%)
6 1 (0.4%) 0 (0.0%)
Previous miscarriage
No previous pregnancies 107 (42.8%) 99 (39.1%)
0 60 (24.0%) 65 (25.7%)
1 50 (20.0%) 49 (19.4%)
2 17 (6.8%) 29 (11.5%)
3 7 (2.8%) 6 (2.4%)
4 6 (2.4%) 1 (0.4%)
5 1 (0.4%) 3 (1.2%)
6 2 (0.8%) 1 (0.4%)
Medical conditions
Hypertension 4 (1.6%) 8 (3.2%)
Insulin-dependent diabetes 2 (0.8%) 3 (1.2%)
Respiratory disease 11 (4.4%) 13 (5.1%)
Cardiac disease 5 (2.0%) 3 (1.2%)
Neurological disease 3 (1.2%) 3 (1.2%)
Skin condition 3 (1.2%) 3 (1.2%)
Thrombophilia 1 (0.4%) 3 (1.2%)
Current pregnancy
Fetal anomaly scan—twin 1
Normal 198 (79.2%) 209 (82.6%)
Defined abnormality 4 (1.6%) 2 (0.8%)
Uncertain abnormality 2 (0.8%) 1 (0.4%)
Not done 43 (17.2%) 40 (15.8%)
Fetal anomaly scan—twin 2
Normal 199 (79.6) 211 (83.4)
Defined abnormality 0 0
Uncertain abnormality 3 (1.2%) 1 (0.4%)
Not done 43 (17.2%) 40 (15.8%)
Chorionicity
Monochorionic diamniotic 50 (20.0%) 51 (20.2%)
Dichorionic diamniotic 200 (80.0%) 202 (79.8%)
Data are given as n (percent) unless otherwise indicated.
https://doi.org/10.1371/journal.pmed.1003506.t001
PLOS MEDICINE STOPPIT 2
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003506 March 29, 2021 9 / 18
cases (S3 Table). Once the pessary had been inserted, the majority of women reported feel-
ing the pessary either never or less than once a week, and rarely found it uncomfortable or
painful (S3 Table). Removal was considered painless or uncomfortable in 95/230 (41.3%)
women and was described as easy or moderately easy in 134/230 cases (58.3%) by clinicians
(S3 Table).
Table 2AU : PleasecheckthattheeditstothecolumnheadsforTables2; 3; 5; 6; and7correctlydescribethecontentsofeachcolumn:Ifnot; pleaseprovidecorrectwording:. Primary obstetric outcome and key subgroup an lyses.





Delivery before 34 weeks 46 (18.4%) 52 (20.6%) 0.87 (0.55, 1.38) 0.88 (0.66, 1.16) 0.54
Primary obstetric outcome by subgroup
Monochorionic pregnancy 10/50 (20.0%) 6/51 (11.8%) 1.57 (0.34, 7.18) 1.67 (0.46, 6.06) 0.44
Dichorionic pregnancy 36/200 (18.0%) 46/202 (22.8%) 0.77 (0.39, 1.50) 0.78 (0.52, 1.18) 0.31
Cervical length� 28 mm 27/89 (30.3%) 23/71 (32.4%) 0.85 (0.33, 2.19) 0.94 (0.60, 1.48) 0.40
Cervical length > 28 mm 19/161 (11.8%) 29/182 (15.9%) 0.72 (0.31, 1.67) 0.71 (0.39, 1.30) 0.31
Cervical length� 25 mm 17/58 (29.3%) 18/39 (46.2%) 0.50 (0.15, 1.63) 0.66 (0.39, 1.14) 0.13
Cervical length > 25 mm 29/192 (15.1%) 34/214 (15.9%) 0.93 (0.45, 1.94) 0.92 (0.58, 1.45) 0.80
For the obstetric outcome, the odds ratio shown is adjusted for chorionicity, with a random effect for centre, and uses a mixed effects model. The risk ratio is adjusted
for chorionicity and uses a generalised linear model clustering on centre. The subgroup analyses also include a variable for the subgroup and the interaction between the
pessary variable and the subgroup variable.
https://doi.org/10.1371/journal.pmed.1003506.t002
Table 3. Primary composite neonatal outcome, components, and key subgroup analyses.





Composite neonatal outcome 67 (13.4%) 76 (15.0%) 0.86 (0.54,1.36) 0.88 (0.60, 1.31) 0.52
Components of neonatal outcome
Stillbirth or neonatal death 22 (4.4%) 28 (5.5%)
Periventricular leukomalacia 5 (1.0%) 1 (0.2%)
Early respiratory morbidity 36 (7.2%) 46 (9.1%)
Intraventricular haemorrhage 9 (1.8%) 6 (1.2%)
Necrotising enterocolitis 2 (0.4%) 10 (2.0%)
Proven sepsis 9 (1.8%) 4 (0.8%)
Primary neonatal outcome by subgroup
Monochorionic pregnancyAU : Thelowerboundof95%CIfortheRRformonochorionicpregnancyismissingadecimalplacevalue : Pleaseprovide; ifpossible; forconsistencywithothervalues:22/100 (22.0%) 13/102(12.7%) 1.89 (0.51, 7.00) 1.69 (0.50, 5.02) 0.21
Dichorionic pregnancy 45/400 (11.3%) 63/404 (15.6%) 0.67 (0.34, 1.34) 0.71 (0.39, 1.29) 0.14
Cervical length� 28 mm 41/178 (23.0%) 28/142 (19.7%) 1.19 (0.47, 3.00) 1.15 (0.56, 2.38) 0.63
Cervical length > 28 mm 26/322 (8.1%) 48/364 (13.2%) 0.57 (0.24, 1.33) 0.61 (0.28, 1.31) 0.09
Cervical length� 25 mm 29/116 (25.0%) 20/78 (25.6%) 1.04 (0.32, 3.33) 1.05 (0.44, 2.50) 0.93
Cervical length > 25 mm 38/384 (9.9%) 56/428 (13.1%) 0.70 (0.34, 1.46) 0.74 (0.38, 1.41) 0.21
For the neonatal outcome, the odds ratio is adjusted for chorionicity and clustering at the mother level using standard logistic regression. The risk ratio is adjusted for
chorionicity and clustering on centre using a generalised linear model. Out of 491 mothers, 399 had no primary neonatal outcomes for either twin, 41 had a primary
neonatal outcome for 1 twin, and 51 had at least 1 primary neonatal outcome for both twins. For 3 centres, the minimum number of neonatal events was 2 (2 centres)
and the maximum was 18 (1 centre).AU : Pleasecheckthelogic=meaningofthesentencethatstarts}For3centres . . . :}Thesentenceseemstosaythattheminimumnumberofneonataleventswas2for5=3ð?Þcentres:Pleaseprovidecorrectwording:
https://doi.org/10.1371/journal.pmed.1003506.t003
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Cervical length profilesAU : Pleasecheckthattheeditstotheparagraph}Cervicallengthprofiles . . . }captureyourmeaning   inparticularthatð1Þ}screeningandrandomisationphasesofthestudy}iscorrectandð2Þtherangesinparenthesesarecorrectlyidentifiedas95%CIs:Ifnot; pleaseprovidecorrectwording:of wom n in the screening and randomis tion phases of the study
are shown in S4 Fig (note that the data in this figure are from the screened population and not
the trial population). The positive and negative likelihood ratios of a short cervix (�35 mm) to
predict preterm birth before 34 weeks were 2.14 (95% CI 1.67–2.74) and 0.83 (95% CI 0.76–
0.90), respectively (S4 Table). For the other cervical lengths (�30 mmm,�28 mm,�25 mm,
and�20 mm), negative likelihood ratios were all more than 0.8, and positive likelihood ratios
ranged from 3.27 to 9.13.
Table 4. Secondary obstetric outcomes.




Mean difference (95% CI) p-Value
Gestational age at delivery (weeks) 34.8 (3.7) [N = 246] 34.5 (4.0) [N = 245] 0.2 (−0.6, 1.1) 0.50
Duration of labour stage 1 (minutes) 403.9 (510.8) [N = 81] 326.0 (255.5) [N = 81] 77.1 (−85.2, 239.4) 0.22
Duration of labour stage 2 (minutes) 80.0 (90.7) [N = 77] 101.1 (202.3) [N = 80] −21.3 (−85.7, 43.1) 0.39
Duration of labour overall (minutes) 333.4 (485.1) [N = 123] 325.7 (439.9) [N = 117] 5.4 (−147.5, 158.3) 0.93
Duration of hospital stay (days) 5.5 (7.2) [N = 243] 5.6 (5.4) [N = 242] −0.1 (−1.6, 1.4) 0.87
Outcome—n (%) Arabin pessary Standard treatment Chi2 p-Value
Method of delivery—twin 1 chi2(3) = 0.835 0.84
Spontaneous vaginal delivery 62 (24.8) 63 (24.9)
Vaginal breech 3 (1.2) 4 (1.6)
Forceps or ventouse 20 (8.0) 15 (5.9)
Cesarean section 160 (64.0) 159 (62.8)
Method of delivery—twin 2 chi2(3) = 3.338 0.34
Spontaneous vaginal delivery 48 (19.2) 45 (17.8)
Vaginal breech 13 (5.2) 23 (9.1)
Forceps or ventouse 15 (6.0) 12 (4.7)
Cesarean section 169 (67.6) 162 (64.0)
Outcome—n (%) Arabin pessary Standard treatment Odds ratio (95% CI) p-Value
Births
Before 28 + 0 weeks 17 (6.8) 24 (9.5) 0.67 (0.27, 1.64) 0.25
Before 32 + 0 weeks 35 (14.0) 41 (16.2) 0.83 (0.42, 1.63) 0.47
Before 34 + 0 weeks 62 (24.8) 66 (26.1) 0.90 (0.52, 1.57) 0.64
Before 37 + 0 weeks 158 (63.2) 161 (63.6) 0.95 (0.57, 1.58) 0.79
Births preceded by spontaneous onset of labour
All births 61 (24.4) 71 (28.1) 0.82 (0.48, 1.41) 0.34
Before 28 + 0 weeks 13 (5.2) 19 (7.5) 0.64 (0.23, 1.77) 0.26
Before 32 + 0 weeks 26 (10.4) 32 (12.6) 0.79 (0.37, 1.68) 0.43
Before 34 + 0 weeks 37 (14.8) 46 (18.2) 0.77 (0.40, 1.47) 0.30
Before 37 + 0 weeks 56 (22.4) 66 (26.1) 0.81 (0.47, 1.41) 0.32
pPROM 12 (4.8) 4 (1.6) 1.95 (0.52, 7.34) 0.20
Incidence of birth before 34 + 0 weeks preceded by pPROM 8 (3.2) 3 (1.2) 1.61 (0.36, 7.14) 0.41
Adverse events
Infection 12 (4.8) 10 (4.0) 1.25 (0.39, 3.95) 0.62
Haemorrhage 115 (46.0) 105 (41.5) 1.19 (0.73, 1.94) 0.35
Tachycardia 6 (2.4) 7 (2.8) 0.70 (0.12, 4.17) 0.61
p-Values are for proportion in Arabin pessary versus standard treatment group from linear regression analysis or using proportional odds analysis, both adjusting for
chorionicity and centre. pPROM, preterm premature rupture of membranes.
https://doi.org/10.1371/journal.pmed.1003506.t004
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Meta-analysis
Electronic searches for clinical trials of the cervical pessary in twin or higher multiple preg-
nancy compared to placebo or standard care, and using the terms cervical pessary AND
preterm birth AND multiple pregnancy, revealed 10 relevant publications. Of these, 3
Table 5AU : InTable5; thep   valuefor}cumulativeinpatientdays}wasroundedfrom0:286to0:29; tomatchothervalues:. Seco d ry neonatal outcomes.
Outcome—mean (SD) or median (minimum, maximum) Arabin pessary Standard treatment Difference in means (95% CI) p-Value
Birthweight (g) 2,170 (659) [N = 488] 2,142 (686) [N = 485] 27 (−120, 174) 0.64
Cord pH (venous) 7.3 (3.4, 7.8) [N = 212] 7.3 (3.3, 7.4) [N = 192] 0.0 (−0.1, 0.0) 0.52
Cord pH (arterial) 7.3 (7.0, 7.4) [N = 199] 7.3 (3.4, 8.3) [N = 177] 0.0 (−0.0, 0.1) 0.09
Apgar score at 1 minute 9.0 (0, 10) [N = 472] 9.0 (0, 10) [N = 470] 0.1 (−0.3, 0.6) 0.46
Apgar score at 5 minutes 9.0 (0, 10) [N = 468] 9.0 (0, 10) [N = 467] 0.1 (−0.3, 0.5) 0.54
Days of oxygen therapy 21.5 (32.9) [N = 36] 9.3 (15.0) [N = 45] 12.9 (−4.0, 29.8) 0.05
Level of care daysAU : Notclearwhat}Levelofcaredays}means:Irecommendrewording:22.0 (27.5) [N = 245] 25.0 (31.8) [N = 225] −4.3 (−13.0, 4.5) 0.21
Cumulative inpatient days 19.6 (41.3) [N = 244] 21.8 (44.9) [N = 244] −2.2 (−12.3, 7.9) 0.29




Odds ratio (95% CI) p-Value
Birthweight < 10th centile 104 (20.8) 97 (19.2) 1.09 (0.69, 1.72) 0.64
Received resuscitation 119 (23.8) 125 (24.7) 0.93 (0.57, 1.52) 0.71
Fetal or neonatal death within the first 28 days after birth 4 (0.8) 8 (1.6) 0.49 (0.07, 3.25) 0.33
Received surfactant 39 (7.8) 40 (7.9) 0.97 (0.45, 2.08) 0.92
Bronchopulmonary dysplasia 6 (1.2) 3 (0.6) 2.00 (0.24, 16.58) 0.40
Necrotising enterocolitis 2 (0.4) 10 (2.0) 0.20 (0.03, 1.50) 0.04
Discrete episodes of bloodstream or CNS infection 3 (0.6) 2 (0.4) 1.50 (0.14, 15.76) 0.66
Daily level of care
Normal care 67 (13.4) 59 (11.7) 1.15 (0.61, 2.16) 0.56
Special care 208 (41.6) 197 (38.9) 1.09 (0.70, 1.69) 0.61
High dependency 87 (17.4) 108 (21.3) 0.76 (0.45, 1.28) 0.18
Intensive 72 (14.4) 72 (14.2) 1.00 (0.54, 1.82) 0.98
Rate of major adverse neonatal outcomes before discharge from hospital 121 (24.2) 128 (25.3) 0.92 (0.57, 1.50) 0.67
Data refer to all twins, with the 95% CIs and p-values adjusted for clustering within twins. CNS, central nervous system.
https://doi.org/10.1371/journal.pmed.1003506.t005
Table 6. Primary obstetric outcome and key subgroup analyses per protocol analysis.





Delivery before 34 weeks 44 (19.1%) 52 (20.6%) 0.87 (0.55, 1.38) 0.91 (0.69, 1.20) 0.50
Primary obstetric outcome by subgroup
Monochorionic pregnancy 10/47 (21.3%) 6/51 (11.8%) 1.57 (0.34, 7.18) 1.78 (0.49, 6.47) 0.44
Dichorionic pregnancy 34/183 (18.6%) 46/202 (22.8%) 0.77 (0.39, 1.50) 0.80 (0.52, 1.22) 0.31
Cervical length� 28 mm 26/85 (30.6%) 23/71 (32.4%) 0.85 (0.33, 2.19) 0.94 (0.59, 1.49) 0.40
Cervical length > 28 mm 18/145 (12.4%) 29/182 (15.9%) 0.72 (0.31, 1.67) 0.75 (0.41, 1.38) 0.31
Cervical length� 25 mm 16/55 (29.1%) 18/39 (46.2%) 0.50 (0.15, 1.63) 0.65 (0.37, 1.15) 0.13
Cervical length > 25 mm 28/175 (16.0%) 34/214 (15.9%) 0.93 (0.45, 1.94) 0.97 (0.61, 1.54) 0.80
For the obstetric outcome, the odds ratio shown is adjusted for chorionicity, with a random effect for centre, and uses a mixed effects model. The risk ratio is adjusted
for chorionicity and uses a generalised linear model clustering on centre. The subgroup analyses also include a variable for the subgroup and the interaction between the
pessary variable and the subgroup variable.
https://doi.org/10.1371/journal.pmed.1003506.t006
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publications were protocols and 3 were secondary analyses, leaving 4 published original studies
[3,6–8]. Three studies used the Arabin cervical pessary [3,7,8]. One [6] used the Bioteque cup
pessary (Bioteque, Fremont, CA, US), which is similar but not identical to the Arabin pessary.
Alternative searches using the terms ‘twin pregnancy’ instead of ‘multiple pregnancy’ and
‘Arabin pessary’ instead of ‘cervical pessary’ did not identify any additional published trials.
Meta-analysis of the data from STOPPIT-2 and from the 4 trials described above on women
with a multiple/twin pregnancy and a short cervix (as defined by the paper authors) showed
considerable heterogeneity amongst the studies (I2 65.8%), with a risk ratio of birth before 34
weeks of gestation following Arabin pessary placement of 0.74 (95% CI 0.50–1.11; p = 0.15)
(Fig 2). A sensitivity analysis restricting analysis to studies with the Arabin pessary (and there-
fore excluding the study with the Bioteque pessary) gave a risk ratio of 0.71 (95% CI 0.45–1.12;
p = 0.14).
Discussion
In this trial, insertion of an Arabin pessary did not reduce the incidence of either the primary
obstetric outcome of preterm birth before 34 weeks of gestation following spontaneous onset
of labour or the composite (or individual) adverse neonatal outcomes. Although the point esti-
mate of the obstetric outcome might indicate benefit for those in the shortest cervix groups
(�25 mm or�28 mm), the point estimate of the neonatal outcome suggests the pessary
could cause harm in these shorter cervix subgroups. None of these results reach statistical
significance.
Our results accord with some [6,8] but not all [3,7] other efficacy or effectiveness studies in
twin or higher multiple pregnancies. Our meta-analysis demonstrates considerable heteroge-
neity amongst existing published studies but shows an risk ratio of the effect of the pessary
in preventing birth before 34 weeks of gestation is 0.74 (95% CI 0.50–1.11). In viewAU : Pleasecheckthattheeditstothesentence}Inviewof . . . }captureyourmeaning:Ifnot; pleaseprovidecorrectwording:of the
Table 7. Primary composite neonatal outcome, components and key subgroup analyses–per protocol.





Composite neonatal outcome 66 (14.3%) 76 (15.0%) 0.93 (0.58, 1.47) 0.94 (0.64, 1.40) 0.74
Components of neonatal outcome
Stillbirth or neonatal death 22 (4.8%) 28 (5.5%)
Periventricular leukomalacia 5 (1.1%) 1 (0.2%)
Early respiratory morbidity 35 (7.6%) 46 (9.1%)
Intraventricular haemorrhage 9 (2.0%) 6 (1.2%)
Necrotising enterocolitis 2 (0.4%) 10 (2.0%)
Proven sepsis 9 (2.0%) 4 (0.8%)
Primary neonatal outcome by subgroup
Monochorionic pregnancy 22/94 (23.4%) 13/102 (12.7%) 2.05 (0.55, 7.63) 1.80 (0.61, 5.33) 0.16
Dichorionic pregnancy 44/366 (12.0%) 63/404 (15.6%) 0.72 (0.36, 1.45) 0.76 (0.41, 1.38) 0.23
Cervical length� 28 mm 41/170 (24.1%) 28/142 (19.7%) 1.25 (0.49, 3.16) 1.19 (0.58, 2.46) 0.54
Cervical length > 28 mm 25/290 (8.6%) 48/364 (13.2%) 0.61 (0.26, 1.45) 0.65 (0.30, 1.41) 0.14
Cervical length� 25 mm 29/110 (26.4%) 20/78 (25.6%) 1.09 (0.34, 3.50) 1.08 (0.46, 2.57) 0.85
Cervical length > 25 mm 37/350 (10.6%) 56/428 (13.1%) 0.76 (0.36, 1.59) 0.79 (0.41, 1.52) 0.33
For the neonatal outcome, the odds ratio is adjusted for chorionicity and clustering at the mother level using standard logistic regression. The risk ratio is adjusted for
chorionicity and clustering on centre using a generalised linear model.
https://doi.org/10.1371/journal.pmed.1003506.t007
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heterogeneity of results of existing studies, the size of STOPPIT-2 (with the short cervix group
being twice as big as the largest previously published study, and with a larger number of events
than any previous study, to our knowledge), the use of a population threshold for cervical
length in STOPPIT-2, and the ‘real world’ setting of STOPPIT-2, we believe our results (OR
0.87 [95% CI 0.55 to 1.38]) should prompt a change in practice for those clinicians currently
using the pessary. A caveat is that we cannot exclude a benefit in a subgroup that is yet to be
identified, particularly given many potential causes of short cervical length. Additionally,AU : Pleasecheckthattheeditstothesentence}Additionally . . . }captureyourmeaning:Ifnot; pleaseprovidecorrectwording:
although the point estimate of the neonatal outcome shows harm in all subgroups of concern
—monochorionic pregnancy, cervical length� 28 mm, and cervical length� 25 mm—the
study is underpowered to be conclusive about subgroup analyses.
The strengthsAU : Pleasecheckthattheeditstothesentence}Thestrengths . . . }captureyourmeaning:Ifnot; pleaseprovidecorrectwording:of our study are that reatment wa allocated by central randomisation, and
that the study used prespecified primary endpoints and followed a prespecified analysis plan.
There was a low rate of loss to follow-up. Adherence was good; the vast majority of women in
the pessary group had the pessary inserted (92%), and all pessaries were inserted by a clinician
who had had specific training in this procedure. Only 26/230 (11.3%) women asked for the
pessary to be removed prematurely: In these women, the median (SD) duration of adherence
was 14 days. We achieved our prespecified sample size of 500 women randomised. A caveat is
that we cannot exclude a small benefit (or harm): Although we achieved our prespecified sam-
ple size, there were fewer events than expected in the standard care alone group (52 and not
88). Hence the confidence intervals for our primary outcomes are larger than anticipated.
Insertion of the pessary had no effect on any secondary or safety outcome, and the majority
of women found pessary insertion, their experience of the pessary during pregnancy, and pes-
sary removal to be associated only with slight discomfort. Clinicians largely found pessary
insertion easy, and placement was not possible in only 1.7% of women. We had intended to
recruit women with cervical lengths at or below the 30th centile. We estimated this to a cervical
length of 35 mm or below. Retrospective analysis showed that the 30th centile for the entire
screening population was a cervical length of 36 mm.
The positive and negative likelihood ratios for a short cervix of�35 mm to predict pre-
term-labour-induced birth before 34 weeks were 2.14 and 0.83, respectively. Whilst these data
suggest some association between short cervix and spontaneous preterm birth, the negative
Fig 2. Meta-analysis of STOPPIT-2 and published data on the effectiveness of a cervical pessary in twin
pregnancies in women with a short cervix in the prevention of preterm birth before 34 weeks gestation.
https://doi.org/10.1371/journal.pmed.1003506.g002
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likelihood ratios for none of the 5 chosen cervical lengths achieved the threshold suggested for
a moderately effective ‘rule out’ test [14]. In contrast, the positive likelihood ratios for cervical
lengths of�20 mm and�25 mm for spontaneous preterm birth before 34 weeks were 9.13
and 7.82, respectively, values which confer moderate utility for a ‘rule in’ test [14]. We are con-
fident that these likelihood ratios are close to the likelihood ratios in the population, given the
size of our prospective cohort study [13,15]. Our data suggest that, as in singleton pregnancy,
spontaneous preterm labour in twin pregnancy has multiple aetiologies, some but not all of
which lead to cervical shortening in the second trimester of pregnancy.
Meta-analysis of our own and existing published studies confirms that the cervical pessary
is not associated with a significant reduction in birth before 34 weeks of gestation in women
with twin pregnancy.
Study limitations
The main study limitations are the lack of power to show a smaller than 40% reduction in the
primary obstetric outcome or to identify an effect in any of the cervical length subgroups, and
the fewer than expected events in the standard care alone group, leading to wider confidence
intervals than anticipated for the primary outcome.
Our findings suggest that the pessary should not be offered to women with twin pregnancy
and a short cervix for the purpose of preventing preterm labour leading to preterm birth, and
that routine cervical length scanning in otherwise uncomplicated twin pregnancies should not
be introduced into routine clinical practice.
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